|
| Author | Study size | Probiotic | Study type | Result |
|
| Sakamoto et al. [33] | 31 | Lactobacillus gasseri OLL2716 | A randomized, controlled clinical trial | Value of UBT decreases. Examination of antral biopsies showed two- to 100-fold decreases in the numbers of HP, but in no case were bacteria eliminated completely. |
| Cruchet et al. [34] | 326 | Lactobacillus johnsonii La1 | A double-blind, randomized, controlled clinical trial | A significant difference (DOB2–DOB1) was detected (−7.64 per thousand; 95% CI: −14.23 to −1.03) |
| Linsalata et al. [52] | 22 | Lactobacillus brevis | A randomized, double-blind, placebo-controlled study | Reduction in the UBT delta values |
| Imase et al. [36] | 179 | L. reuteri | A randomized, double-blind, crossover study | Administration of L. reuteri tablets significantly decreased UBT in HP-positive subjects |
| Rosania et al. [53] | 80 | A mixture of 8 different probiotics | Double-blind, placebo-controlled, randomized | Eradication rate
Probiotic: 32.5%
Placebo: 0% |
| Francavilla et al. [54] | 100 | L. reuteri DSM 17938 + L. reuteri ATCC PTA 6475 | Double-blind, placebo-controlled, randomized | Probiotic: a decrease in the 13C-UBT value by 13%
Placebo: a 4% increase |
| Holz et al. [55] | 128 subjects, 47 twin pairs, and 34 singletons | L. reuteri DSM 17648 | Placebo-controlled pilot study | Had unique properties as it specifically aggregates with planktonic HP in the stomach. It can significantly reduce the HP load after a 14-day oral treatment |
|
